Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LunaRx vs Nucific

LunaRx
Graded #299

Higher grade

vs+5
Nucific
Graded #417

Lower grade

The verdict

LunaRx takes it — 61.2/100 to 56.2/100.

LunaRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LunaRx is a bilingual (English/Spanish) telehealth practice from LunaRx LLC built around "metabolic recomposition" — compounded GLP-1 therapy paired with muscle-protective peptides and a structured off-ramp…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLunaRx +9
54
45
Dose & formulationNucific +1
52
53
Clinical oversightLunaRx +6
82
76
Labs & monitoringLunaRx +2
54
52
FulfillmentLunaRx +3
70
67
Contract termsLunaRx +14
55
41
LunaRx · left barNucific · right bar

The numbers

MetricLunaRxNucific
WeighScore61.2/10056.2/100
GradeCC
Scorecard rank#299#417
Semaglutide$199/mo (starting dose, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
LunaRx

Graded #299 · C

Strengths

  • Pairs GLP-1 with muscle-protective peptides (e.g., CJC-1295/Ipamorelin, NAD+) to defend lean mass during fat loss
  • Structured, physician-directed off-ramp taper with GI-reset support instead of an indefinite prescription
  • Bilingual care in English and Spanish across intake, messaging, and consults
  • Care directed through a named independent medical group (CareNexus Clinic PC); $0 charged if you are not approved
  • Published clinical support hours (Mon–Fri, CT) with phone, email, and secure messaging; cancel anytime

Where it loses points

  • Only a "from $199/mo" starting price is published; tirzepatide and per-tier pricing are confirmed only after a provider review
  • Compounding pharmacy partners are not named on the site — a transparency gap
  • No LegitScript or PCAB verification is displayed
  • States served are not published; the site claims "telehealth nationwide" but the Terms limit service to states where LunaRx is licensed
  • Compounded medications are not FDA-approved (the site discloses this)
Nucific

Graded #417 · C

Strengths

  • Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
  • Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
  • Discloses that featured patients were compensated for their time
  • Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
  • Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue

Where it loses points

  • No price is published anywhere; every option is gated behind a three-minute quiz
  • The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
  • A BBB Accredited A+ claim is displayed without a link to the BBB profile
  • No state list and no named pharmacy, only licensed U.S. pharmacies
  • Before-and-after photographs are used alongside compensated testimonials

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard